Navigation Links
Key growth factor identified in T cell leukemia
Date:8/1/2011

Blocking a growth factor receptor cripples cancer growth in a form of T cell leukemia, according to a study published online on August 1 in the Journal of Experimental Medicine (www.jem.org).

Approximately half of the cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic mutations in a cellular signaling pathway called Notch, which result in aberrant activation of the cell. A study by Andrew Weng and colleagues at the British Columbia Cancer Agency now shows that activation of the Notch pathway promotes the expression of a receptor for insulin growth factor (IGF-1), which drives the growth and survival of the cancer cells.

Cancer cells with an activated Notch pathway but lacking the IGF-1 receptor had reduced growth in mice, and blocking the receptor with drugs improved their survival. Simply reducing the amount of receptor resulted in the loss of cancer stem cellsthe cells responsible for originating and perpetuating the disease. Human T-ALL cells were also found to express IGF-1 receptor, suggesting that blocking the receptor in combination with standard treatment may reduce the risk of disease relapse.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert

Page: 1

Related medicine news :

1. Education -- a key determinant of population growth and human well-being
2. Progesterone inhibits growth of neuroblastoma cancer cells
3. Self-referral: A significant factor in imaging growth
4. Hereditary colon cancer syndrome marked by abnormally dense blood vessel growth in mouth
5. Slow growth of childhood brain tumors linked to genetic process seen in skin moles
6. Scientists image beginning stages of ovarian cancer growth with time-lapse technique
7. Cancer cells accelerate aging and inflammation in the body to drive tumor growth
8. Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
9. Enzyme may drive breast cancer growth
10. Artificial tissue promotes skin growth in wounds
11. Obstructive sleep apnea linked to cancer growth in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology: